

1 **Treatment preferences among people at risk of developing tuberculosis: a discrete choice**
2 **experiment**

3

4 Wala Kamchedzera¹, Matthew Quaife², Wezi Msukwa-Panje¹, Rachael M Burke³, Liana
5 Macpherson⁴, Moses Kumwenda¹, Hussein H Twabi^{1,5}, Matteo Quartagno⁴, Peter MacPherson^{1,3,6},
6 Hanif Esmail^{4,7*}

7

8 1. Public Health Research Group, Malawi-Liverpool Wellcome Clinical Research Programme,
9 Blantyre, Malawi

10

11 2. Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population
12 Health, London School of Hygiene and Tropical Medicine, London, England

13

14 3. Clinical Research Department, Faculty of Infectious and Tropical Disease, London School of
15 Hygiene and Tropical Medicine, London, England

16

17 4. MRC Clinical Trials Unit at University College London, London, England

18

19 5. Helse-Nord Tuberculosis Initiative, Kamuzu University of Health Sciences, Blantyre, Malawi

20

21 6. School of Health and Wellbeing, University of Glasgow, Glasgow, Scotland

22

23 7. WHO Collaborating Centre on Tuberculosis Research and Innovation, Institute for Global
24 Health, University College London

25 *Corresponding author

26 E-mail: h.esmail@ucl.ac.uk (HE)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Abstract

28 Diagnosing and treating tuberculosis (TB) early, prior to bacteriological confirmation (e.g.
29 bacteriologically-negative but radiologically-apparent TB) may contribute to more effective TB care
30 and reduce transmission. However, optimal treatment approaches for this group are unknown. It is
31 important to understand peoples' preferences of treatment options for effective programmatic
32 implementation of people-centred treatment approaches.

33 We designed and implemented a discrete choice experiment (DCE) to solicit treatment preferences
34 among adults (≥ 18 years) with TB symptoms attending a primary health clinic in Blantyre, Malawi.
35 Quantitative choice modelling with multinomial logit models estimated through frequentist and
36 Bayesian approaches investigated preferences for the management of bacteriologically-negative, but
37 radiographically-apparent TB.

38 128 participants were recruited (57% male, 43.8% HIV-positive, 8.6% previously treated for TB).
39 Participants preferred any treatment option compared to no treatment (odds ratio [OR]: 0.17; 95%
40 confidence interval [CI]: 0.07, 0.42). Treatments that reduced the relative risk of developing TB disease
41 by 80% were preferred (OR: 2.97; 95% CI: 2.09, 4.21) compared to treatments that lead to a lower
42 reduction in risk of 50%. However, there was no evidence for treatments that are 95% effective being
43 preferred over those that are 80% effective. Participants strongly favoured the treatments that could
44 completely stop transmission (OR: 7.87, 95% CI: 5.71, 10.84), and prioritised avoiding side effects
45 (OR: 0.19, 95% CI: 0.12, 0.29). There was no evidence of an interaction between perceived TB disease
46 risk and treatment preferences.

47 In summary, participants were primarily concerned with the effectiveness of TB treatments and strongly
48 preferred treatments that removed the risk of onward transmission. Person-centred approaches of
49 preferences for treatment should be considered when designing new treatment strategies. Understanding
50 treatment preferences will ensure that any recommended treatment for probable early TB disease is well
51 accepted and utilized by the public.

52

53 Introduction

54 Globally, at least 10 million people fall ill with tuberculosis (TB) every year, and an estimated 1.6
55 million died of TB in 2022 (1). Although some progress has been made in reducing TB incidence and
56 death, particularly in countries that have experienced HIV-driven epidemics in Africa, this has fallen
57 well short of global targets, and has further been worsened by the disruptions to diagnosis and treatment
58 caused by the COVID-19 pandemic (2,3). Additionally, the TB epidemic has become increasingly
59 concentrated in marginalised groups as the overall TB prevalence has reduced (4,5). Therefore, new,
60 person-centred, and effective approaches must be considered to diagnose and treat individuals early.

61 Accelerated approaches are needed to achieve the rapid declines in TB transmission required to
62 eliminate TB. The standard approach to diagnosing disease is through bacteriological confirmation of
63 *Mycobacterium tuberculosis* (*Mtb*) in a biological specimen. It is increasingly being recognised that
64 there are potential opportunities to diagnose and intervene earlier in the disease process prior to
65 bacteriological confirmation which may then contribute to more effective TB prevention and care and
66 interruption in TB transmission (6,7). There are several tests that have been proposed that could identify
67 people during this earlier stage of disease some of which are established, with others currently in
68 development. People with chest X-ray (CXR) signs suggestive of TB, but with negative sputum
69 bacteriology, have an annualised risk of progression to bacteriologically-positive TB of 10%, with an
70 estimated 26% progressing to sputum positivity over 3 years (8). Blood transcriptional signatures are
71 predictive of disease progression over 0-12 months with a positive predictive value of (PPV) of 8.3-
72 10.3% (9).

73 The development of diagnostics that can predict disease progression has been identified as a research
74 priority by WHO (10). However, in recent years, there has been little attention given to the appropriate
75 treatments for people with earlier stages of TB. Firstly, they may have more limited disease requiring
76 less intense or shorter treatment duration than is used for bacteriologically positive disease (11). Second,
77 a positive test predictive of disease progression does not guarantee disease progression. Analyses of
78 historic trials providing treatment to people with CXR changes suggestive of active TB with negative

79 bacteriology showed number needed to treat to prevent a case of bacteriologically positive TB was 2.5,
80 which is considerably lower than that for preventive treatment of latent TB infection in a general
81 population(12). Modern clinical trials to determine the optimal approach to treatment for probable early
82 TB are needed. However, whilst these are being undertaken (13), it is important to better understand
83 the treatment preferences of people in these earlier stages of TB disease to inform the design of these
84 trials and facilitate more effective programmatic implementation of new treatment approaches.

85 We therefore conducted the Radio+ TB Study in Malawi to investigate the role of digital chest
86 radiography with computer-aided detection of TB (DCXR-CAD) and a novel transcriptional marker for
87 TB diagnosis and prognosis. Embedded in this study, we conducted a discrete choice experiment
88 (DCE). DCEs are a widely-used tool to measure patients' preferences for service characteristics (14–
89 16). They have been shown to accurately predict individuals' preferences and choices regarding
90 healthcare services (17). In DCEs, study participants make several choices between interventions
91 (alternatives) that have different levels of the same characteristics (attributes). It is assumed that
92 individuals derive utility from these individual attributes, and thus their preferences can be analysed
93 through studying their choices in DCEs(18).

94 Using a DCE, we aimed to investigate people's preferences for the management of the scenario of
95 having bacteriologically-negative sputum but with a moderate to high risk of future progression to
96 bacteriologically positive TB.

97 **Materials and methods**

98 We used a cross-sectional DCE study design to elicit people's preferences for the management of early
99 TB disease.

100 **Study setting & population**

101 The study took place at a busy urban primary healthcare centre in Blantyre, Malawi (Bangwe Health
102 Centre). The annualised TB case notification rate in Blantyre was 152 per 100,000 in 2020 (19). In
103 Blantyre 15% of adults aged 18 years or older are living with HIV (20). TB diagnostic services available

104 at Bangwe Health Centre follow standard Malawi Ministry of Health guidelines (21). Sputum Xpert
105 MTB/Rif testing, TB treatment provision, and HIV testing and treatment were available onsite, with all
106 clinical care provided by nurses and clinical officers, with no physicians available. At the time of the
107 study, there were no treatment guidelines for early TB disease at the clinic. People with signs and
108 symptoms of TB but bacteriologically-negative sputum typically do not start TB treatment, although on
109 occasion might be referred to a tertiary hospital for further investigations or have empiric TB treatment
110 started at the primary healthcare clinic (at the discretion of the treating nurse or clinical officer).

111 The present study recruited participants enrolled in the Radio+ TB diagnostic study, which included
112 adults of at least 18 years of age, irrespective of HIV status, presenting to the study clinic with TB
113 symptoms (cough of any duration) and residing in Blantyre. For this cross-sectional DCE survey, 128
114 Radio+ TB study participants were consecutively recruited after clinical assessment, which included
115 CXR analysed with CAD4TBv6, sputum investigations, and blood testing with a TB Host Response
116 blood test developed by Cepheid (Sunnyvale, Ca, USA), but before any results or treatment were
117 provided. Therefore, whether or not the participant actually had bacteriologically-negative sputum and
118 abnormal CXR was not part of the inclusion criteria.

119 **Design and development of the DCE tool**

120 **Identification of attributes**

121 To design the DCE tool, attributes of TB management were systematically identified. An initial list of
122 attributes was obtained from reviewing literature for the management of TB disease and treatment
123 preference studies. We kept our search broad and did not limit the list to the management of people
124 with a high risk of TB disease, as the literature in this area is limited and treatment guidelines for this
125 group have not been clearly defined. The list was further informed by policy documents such as Malawi
126 National TB and Leprosy Elimination Programme manuals and TB management guidelines.

127 To further inform the list of attributes and levels, we conducted qualitative interviews to ensure options
128 were appropriate for the context in which the study would take place. The aim of these qualitative
129 interviews was to identify important factors of the management of early TB disease. In-depth interviews

130 were conducted with participants enrolled into the wider diagnostics study. Participants were
 131 purposively sampled to achieve a 1:1 ratio of men to women. Saturation of information was reached at
 132 20 participants. Data were iteratively coded using Nvivo 12, and thematic analysis was employed. Study
 133 procedures and results are reported elsewhere. Table 1 illustrates the final list of attributes and levels.

134 **Table 1:** Final list of attributes and levels

Attribute	Explanation presented to the participant	Attribute Levels
Duration of treatment	The length of time you would have to take treatment if you were at risk of developing TB disease.	<ul style="list-style-type: none"> - 2 months - 3 months - 4 months - 5 months - 6 months
Number of tablets that should be taken per dose	How many tablets you would have to take per dose	<ul style="list-style-type: none"> - 2 tablets per dose. - 4 tablets per dose. - 6 tablets per dose.
The reduction in the risk of being unwell with TB disease, after completing treatment	Your risk of TB disease after completing treatment will reduce from 30% to 15% (if attribute level is a 50% reduction).	<ul style="list-style-type: none"> - 50% - 65% - 80% - 95%
Likelihood of infecting others	Whether you can still infect others after completing treatment.	<ul style="list-style-type: none"> - Does not stop you from passing TB on to others. - Reduces the chances of passing TB on to others by half. - Will completely stop you from passing TB on to others.
Adverse effects from the treatment	Possible harmful side effects from the treatment.	<ul style="list-style-type: none"> - No side effects. - Minimal side effects -generally not noticeable such as brief feeling of sickness. - Mild side effects present each day – may make you feel like not enjoying socializing but able to work. - Moderate side effects – Bad enough to stop work and see nurse/doctor for help.
Frequency of follow up irrespective of treatment.	How often you would have to be checked on by health workers.	<ul style="list-style-type: none"> - None - Once a month - 3 times a month
Annual travel cost to access care (USD\$)*	How much you would spend travelling from your home to a healthcare facility to access care in a year.	<ul style="list-style-type: none"> - \$0 - \$2.95 - \$7.38

135 *Costs in the DCE tool were expressed in Malawi Kwacha (MKW).USD\$1.00 = MKW812.51 as of

136 14/09/21 (22)

137 Experimental design and construction of DCE choice sets

138 In constructing the choice sets for the DCE, using a full factorial design would be the most balanced
139 and orthogonal as it contains all possible combinations of attributes and levels (23). However, with a
140 total of 7 attributes and 25 levels this would result in 1024 ($4^3 \times 2^4 \times 1^5$) choice sets, which was
141 impractically large and would result in respondent fatigue (23). Therefore, to make the task manageable,
142 we used a fractional factorial design (23,24), whereby participants were exposed to a random selection
143 of 10 choice sets from the full factorial design.

144 Using the initial choice set we conducted two iterations of cognitive interviews among five participants.
145 We aimed to investigate whether the formulated DCE was comprehensive for the target population.
146 This involved discussions around the presentation and format of the DCE, including the visual aids and
147 wording used. The results of this were then used to iterate and improve upon the DCE tool.

148 Thereafter, we conducted a pilot study among a further five participants to ensure that the most
149 meaningful and efficient design was used for the final study. To ensure the most efficient DCE design
150 was formed, we used NGENE software to formulate different designs that minimised D-error(23). The
151 D-efficiency score refers to the precision with which effects of attributes are estimated in the model
152 (24). Formulation of D-efficient choice sets depends on the planned model specification and the
153 assumed parameter values (23). We therefore used the parameters estimated with the pilot data to act
154 as the assumed parameter values to inform the formulation and selection of the most D-efficient design.
155 We also used the piloting process to identify any areas of the DCE's format and the respective visual
156 aids that needed further improvement.

157 The final DCE included 10 choice tasks. We also included an opt-out option of "neither" to ensure the
158 choices made are realistic in allowing patients not to choose treatment. Each choice task included a
159 scenario, where the participant had negative sputum bacteriology and a CXR result suggestive of TB
160 and underwent a further (unspecified) predictive tests with the result providing a hypothetical risk of
161 disease progression. Participants were therefore asked to make their choices between treatments based
162 on each scenario (e.g.: "if you had a positive test result which means your risk of developing TB disease

163 over the next 12 months is xx%, which treatment would you prefer?”). The risk level of disease
164 progression varied with each choice set (50%, 30%, and 10%). This was done to understand whether
165 the known level of disease risk due to a predictive test could influence treatment preferences. We
166 developed visual aids from the cognitive interviews, which were used to explain the meaning behind
167 the “risk of TB disease progression” and the attributes. To check consistency in choices we randomly
168 picked one choice task to be repeated at the end of the 10 tasks. We also asked the participants to give
169 a reason as to why they have picked a particular treatment option. This was done to ensure choices made
170 were not random or due to decision fatigue (25).

171 Data analysis

172 Data were analysed using STATA v14 (College Station, Texas, US) and R version 4.2.2 (R Foundation
173 for Statistical Computing, Vienna, Austria). Descriptive statistics were used to summarise the data and
174 to investigate the distribution of key participant characteristics within the study population.

175 We employed quantitative choice modelling by using a multinomial logit model to analyse the choices
176 made by the participants. In this model the dependant variable was the choice made by participants
177 between treatments, and independent variables were the different attributes and their respective levels.
178 In such models, it is assumed that individuals derive their utility or satisfaction from the choices made
179 between treatments (18). Therefore, the model-derived coefficients for the different attribute levels
180 provides the marginal effect of each attribute level on the choice of treatment for individuals at risk of
181 TB disease progression, holding all other attributes constant. Coefficients from the multinomial logit
182 model were converted to odds ratios to show the relative effect of each attribute level on the choice of
183 treatment as compared to the attribute’s base level.

184 We further evaluated the interaction between the risk of TB disease progression, taken from the
185 hypothetical scenarios, and the different attribute levels to investigate whether the effect of the attributes
186 on preferences varies by the risk of disease progression. Due to there being an insufficient sample size
187 to observe variations according to disease risk, we employed Bayesian methods to construct a
188 multinomial logit model to estimate possible interaction effects. Priors were weakly regularising. We

189 summarised posterior draws to estimate the percentage point difference and uncertainty in the
190 probability of selecting a treatment option due to an attribute level.

191 Ethical approval

192 Ethical approval was received from the University of Malawi College of Medicine Research Ethics
193 Committee (P.02/21/3271) and University College London Research Ethics Committee (ID Number:
194 19219/001). All participants provided written informed consent. If illiterate, participants were asked to
195 provide a witnessed thumbprint.

196 Results

197 Participants were recruited from the 14th of September 2021 to the 21st of February 2022. Table 2 shows
198 the study participants' characteristics. Of the 128 participants, 57% were male. Most participants were
199 aged between 35 and 44 years (30.5%). Additionally, most participants (84.4%) reported primary
200 education as their highest level of education. 40.6% of participants were self-employed and 23.4%
201 reported having formal employment. The median duration of cough experienced by participants before
202 presenting to the clinic was 21 days (IQR: 14-30). After cough, chest pain was the most common
203 symptom experienced by participants (60.9%). Approximately 8.6% of participants had been previously
204 treated for TB. Just under half of the participants reported being HIV positive (43.8%). During the main
205 study, 10.2% of the participants initiated TB treatment over 6-months of follow-up.

206

207 **Table 2:** Participant Characteristics N=128

Characteristic	N (%)	
Sex	Male	73 (57.0)
	Female	55 (43.0)
Age in years	18-24	24 (18.8)
	25-34	34 (26.6)
	35-44	39 (30.5)
	≥ 45	31 (24.2)
Marital status	Married/cohabiting	86 (67.2)
	Single/ widowed	42 (32.8)
Highest education level obtained	None	6 (4.7)
	Primary	108 (84.4)
	Secondary (MSCE)	10 (7.8)
	Higher education	4 (3.1)
Literacy	Can read	116 (90.6)
	Cannot read	12 (9.4)
Employment	Employed	30 (23.4)
	Self-employed	52 (40.6)
	Student/other	3 (2.3)
	Unemployed	43 (33.6)
Median duration of cough in days (IQR)	21 (14-30)	
Experienced other TB symptoms	Chest pain	78 (60.9)
	Dyspnoea	57 (44.5)
	Feeling weak	51 (39.8)
	Fever	54 (42.2)
	Sweating	52 (40.6)
	Weight loss	74 (57.8)
Previously treated for TB	Yes	11 (8.6)
	No	117 (91.4)
Self-reported HIV status	Positive	56 (43.8)
	Negative	65 (50.8)
	Missing	7 (5.5)

208 MSCE: Malawi School Certificate of Education

209 IQR: Interquartile range. TB: tuberculosis

210 Table 3 shows the results of the initial multinomial logit model. The presented odds ratios show the
211 odds of choosing a treatment due to an attribute level compared to the attribute's base level.

212 There was strong evidence that people valued any treatment option over no treatment ($p < 0.001$).
213 Compared to treatments that did not stop transmission, treatments that reduced the chances of
214 transmission by half had 8.4 (95% confidence interval [CI] 6.12, 11.54) times greater odds of being
215 chosen, and those that completely stopped transmission had 7.87 (95% 5.71, 10.84) times greater odds
216 of being chosen. Participants strongly preferred treatments that reduced their risk of developing TB
217 disease by 80% (odds ratio [OR]: 2.97; 95% CI: 2.09, 4.21) and 95% (OR: 1.95; 95% CI: 1.33, 2.85)
218 compared to treatments that lead to a reduction in risk by 50%.

219 There was strong evidence for participants being opposed to treatments with moderate (OR: 0.19, 95%
220 CI: 0.12, 0.29), mild (OR: 0.22, 95% CI: 0.16, 0.32) and minimal side effects (OR: 0.35, 95% CI: 0.25,
221 0.50) compared to treatments with no side effects. There was evidence that participants did not prefer
222 treatments that had 6 tablets per dose as compared to those with 2 tablets per dose (OR: 0.60; 95% CI:
223 0.40, 0.92). Compared to treatments that did not require any follow-up visits, participants preferred
224 treatments with follow-up visits taking place once a month (OR: 2.57; 95% CI: 1.99, 3.33).

225 There were some counter-intuitive results. With an increase in the number of months required to
226 complete treatment, the odds of participants preferring the treatment also increased (OR: 1.41; 95% CI
227 1.28, 1.56). Additionally, participants preferred treatments with a higher annual travel cost as compared
228 to those that incurred no cost (OR: 3.49; 95% CI: 2.15, 5.67).

229 To check the consistency of participants' choices, task 5 was repeated at the end of all the choice sets
230 in the DCE. Of the 128 participants 80.5% chose the same treatment option.

231

232 **Table 3:** Treatment preferences N=128

Attribute	Level	Odds Ratio (95%CI)	*P-value
Number of tablets per dose	2	1	
	4	0.83 (0.63, 1.08)	0.17
	6	0.60 (0.40, 0.92)	0.02
Duration of treatment (months)		1.41 (1.28, 1.56)	<0.001
Reduction in risk of developing disease after completing treatment	50%	1	
	65%	0.91 (0.67, 1.24)	0.57
	80%	2.97 (2.09, 4.21)	<0.001
	95%	1.95 (1.33, 2.85)	0.001
Likelihood of infecting others with TB disease	Does not stop transmission	1	
	reduces the chances of transmission by half	8.4 (6.12, 11.54)	<0.001
	Completely stops transmission	7.87 (5.71, 10.84)	<0.001
Adverse effects	None	1	
	Minimal	0.35 (0.25, 0.50)	<0.001
	Mild	0.22 (0.16, 0.32)	<0.001
	Moderate	0.19 (0.12, 0.29)	<0.001
Follow up	No follow up	1	
	Once a month	2.57 (1.99, 3.33)	<0.001
	3 times a month	1.31 (1.01, 1.72)	0.05
Annual travel cost	No cost	1	
	USD\$2.95	2.02 (1.04, 3.93)	0.037
	USD\$7.38	3.49 (2.15, 5.67)	<0.001
Opting out of treatment		0.17 (0.07, 0.42)	<0.001

233 CI: Confidence Interval

234 USD\$1.00 = MWK812.51 as of 14/09/22(22)

235 To explore whether quantification of the risk of TB affected the importance of different attributes, the
 236 interaction effect between the risk of TB disease progression and the different treatment attributes were
 237 modelled using a Bayesian multinomial logit model. The results of this are illustrated in Figure 1.
 238 Generally, the results showed that, regardless of the level of disease risk, participants were more likely
 239 to opt for treatment rather than opt out of treatment. There was, however, no significant evidence for a
 240 difference in preferences according to the disease risk level for all treatment attributes.

241

242

243 **Fig 1:** Interaction effect between risk of TB disease progression and treatment attributes N=128

244 USD\$1.00 = MWK812.51 as of 14/09/22(22)

245

246 Discussion

247 We set out to investigate people's preferences for the treatment in the scenario of not having disease
248 bacteriologically confirmed but being presented with a high risk of future disease progression. Our main
249 findings were that, among those at risk of progression to clinical TB, there is a strong preference to take
250 treatment than to not take treatment. This finding was regardless of the level of perceived TB disease
251 risk. Furthermore, strong preferences were shown for treatments that were highly effective, such as
252 treatments preventing transmission and those that would likely reduce the risk of disease progression.
253 The main implications of these findings are that to ensure treatment uptake, new treatment strategies
254 should be highly effective both in treating disease and in reducing the risk of transmission. Additionally,
255 for novel treatments that do provide these benefits, it is important to raise and ensure awareness of these
256 benefits among those seeking healthcare to ensure treatment uptake and adherence.

257 In our study, participants were shown to be primarily concerned with cure. This is demonstrated by the
258 preference of being on any treatment option as opposed to none; and there being a strong preference for
259 treatment options that reduced their risk of TB disease by at least 80% as compared to treatments
260 offering a 50% reduction. This is further illustrated with there being no interaction effect between the
261 risk of disease progression and attribute levels. This is in line with previous studies on preferences for
262 both preventative therapy and treatment for TB as people have been shown to prioritise being
263 completely cleared from infection or disease, and expressed that their motivation for adhering to
264 treatment is the desire to be healthy (26–28).

265 Preferences were strongly dominated by treatment options that reduced the likelihood of *Mtb*
266 transmission. Previous studies employing qualitative interviews and DCEs have shown that a
267 motivating factor for many individuals to initiate preventative TB treatment was to protect close
268 contacts such as family members, especially children (27). Another study looking at public preferences

269 for interventions that prevent infectious diseases demonstrated that most participants preferred control
270 measures such as isolation and quarantine in order to prevent the spread of infection to others (29).
271 Altogether, this suggests that for our study population, protecting others from infection was a main
272 priority.

273 Concerning the features of treatment, preference for a treatment increased with an increase in the
274 duration of treatment. This is against our expectations as previous studies have demonstrated that people
275 prefer treatments of shorter durations and the reasons for this is to minimise the risk of side effects to
276 ensure treatment adherence (27,30). With our DCE study population, it is possible that participants
277 preferred longer durations as opposed to shorter durations because of a lack of confidence in shorter
278 treatments being effective. This may have been influenced by the current TB treatment regimen in
279 Malawi being six months and the participants' strong preference for treatments that are highly effective
280 by reducing their risk of disease progression. Although it is possible that participants were unable to
281 understand the attribute within the DCE or the design of the DCE was not able to effectively measure
282 the participants' preferences, we conducted cognitive interviews before the study to minimise this risk.
283 Further qualitative research is needed to validate and improve our understanding of this result.

284 Our results showed that the experience of taking medication was of high priority. There was preference
285 for treatments with a lower pill burden and no to minimal side effects. A previous study also found that
286 the pill burden of TB treatment had a negative impact on the patient's experience and therefore
287 treatment adherence (28). Similarly, previous studies have shown that people viewed side effects as a
288 barrier to treatment adherence (26,27,30). Side effects arising from TB treatment may hinder an
289 individual's quality of life and ability to take part in income generating activities whilst being on
290 treatment. This is crucial for households in low-income countries such as Malawi.

291 Participants also preferred to have routine follow-up whilst on treatment. However, the optimal
292 frequency of follow-up was once a month. We can speculate that this finding may reflect the awareness
293 of barriers to accessing healthcare in low-income countries, such as distance and poverty (31–33). And
294 once they are at the health facility, individuals often face long waiting times and high costs (33–35).

295 Guo *et al* (2011) showed that participants that were employed preferred less frequent clinic visits whilst
296 taking TB preventive therapy (27). This may be especially true with our study population since the
297 majority are either employed or self-employed. Overall, this suggests that, most people desire routine
298 follow-up; however this should not come at the expense of forgoing work related or productive
299 activities.

300 The odds of picking a treatment increased with cost. This was in contrast to our prior expectations and
301 previous literature (28). It has been shown that high costs act as a barrier to accessing care, and
302 individuals with TB often fall victim to catastrophic expenditure (32,33,36). However, participants
303 preferring to be on any treatment as opposed to no treatment is likely to have driven these results. Opting
304 out of treatment would entail not paying anything as treatment is not being accessed. Therefore, the
305 choice of choosing any treatment option over no treatment would have implied that individuals would
306 rather bear a small cost if it meant being on treatment and getting cured.

307 It is important to note that the participants were presented with all attributes and levels of each treatment
308 option therefore allowing them to weigh the costs and benefits of each treatment. In reality, this is not
309 the case, as not all benefits are made known to individuals in advance of seeking treatment. Therefore,
310 the costs faced can still act as a barrier to seeking care despite the treatment being highly effective.

311 Our results show that 80.5% of the participants selected the same treatment option during the repeated
312 choice tasks. This shows consistency in choices and is broadly in line with other DCEs in the literature,
313 therefore demonstrating internal validity of the results (37).

314 **Study limitations**

315 One limitation of this study is that it was not sufficiently powered to explore heterogeneity in people's
316 preferences for early TB treatment across key demographic characteristics. This type of analysis is
317 important because it acknowledges the fact that the population is not completely homogenous and
318 therefore preferences can be influenced by other factors. Identifying these influencing factors can give

319 us a greater understanding of why different treatments and interventions are accepted at varying degrees
320 in different populations.

321 This study only recruited individuals with TB symptoms presenting to the clinic. However, it is
322 becoming apparent that a significant proportion of individuals with early TB disease can be
323 asymptomatic. As these participants are not experiencing any symptoms, they may not anticipate being
324 put on treatment for an extended period. Therefore, their preferences for treatment may be different
325 from those that are symptomatic. Future studies should explore the preferences of this group as insights
326 from such studies can give further information on how patient-centred approaches for early TB
327 management can be designed.

328 Although we asked the participants why they preferred certain treatment options to ensure choices made
329 were not random or due to fatigue, we did not formally record the decision-making process of our
330 study's participants when choosing between treatment options. This data would have been valuable
331 because it would provide further evidence as to why certain treatment attributes were preferred over
332 others. Therefore, we were only able to speculate as to why certain choices were made when discussing
333 the results of this study. Future DCEs should consider this practice to add depth to the results obtained.

334 Conclusions

335 Our study demonstrates that for the treatment of individuals with a risk of TB disease progression, there
336 is a primary concern with the effectiveness of treatment. Additionally, people will strongly consider
337 taking treatment if it means reducing or removing the risk of transmission. Therefore, new treatment
338 strategies should ensure that the treatment is highly effective in treating TB disease. Furthermore, our
339 results also have implications on how public health messages around new treatment strategies should
340 be presented and packaged to the public. For instance, if people are aware of the reduction in the risk
341 of TB transmission whilst being on treatment they are more likely to desire early TB treatment and
342 therefore achieve individual and community benefits. Concerning treatment characteristics, the persons
343 experience should be considered when designing new treatment strategies as people preferred no to

344 minimal side effects, and fewer tablets per dose. Altogether, this will ensure the treatment is well
345 accepted and utilized by the public.

346 References

- 347 1. World Health Organization. Global tuberculosis report 2023. Geneva; 2023.
- 348 2. World Health Organization. Global Tuberculosis Report 2022. Geneva; 2022.
- 349 3. World Health Organisation. The end TB strategy: Global strategy and targets for tuberculosis
350 prevention, care and control after 2015. Geneva; 2014.
- 351 4. Feasey HRA, Khundi M, Soko RN, Nightingale E, Burke RM, Henrion MYR, et al. Prevalence of
352 bacteriologically-confirmed pulmonary tuberculosis in urban Blantyre, Malawi 2019–20:
353 Substantial decline compared to 2013–14 national survey. *PLOS Global Public Health*. 2023 Oct
354 20;3(10):e0001911.
- 355 5. Khundi M, Carpenter JR, Corbett EL, Feasey HRA, Soko RN, Nliwasa M, et al. Neighbourhood
356 prevalence-to-notification ratios for adult bacteriologically-confirmed tuberculosis reveals
357 hotspots of underdiagnosis in Blantyre, Malawi. *PLOS ONE*. 2022 May 23; 17(5):e0268749.
- 358 6. Esmail H, Cobelens F, Goletti D. Transcriptional biomarkers for predicting development of
359 tuberculosis: progress and clinical considerations. *Eur Respir J*. 2020 Mar 5; 55(3).
- 360 7. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and
361 Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. *Clin
362 Microbiol Rev*. 2018 Jul 18;31(4).
- 363 8. Sossen B, Richards AS, Heinsohn T, Frascella B, Balzarini F, Oradini-Alacreu A, et al. The
364 natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-
365 analysis. *The Lancet Respiratory Medicine*. 2023 Apr 1;11(4):367–79.
- 366 9. Gupta RK, Turner CT, Venturini C, Esmail H, Rangaka MX, Copas A, et al. Concise whole
367 blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level
368 pooled meta-analysis. *The Lancet Respiratory Medicine*. 2020 Apr 1; 8(4):395–406.
- 369 10. World Health Organization. Consensus meeting report: development of a Target Product Profile
370 (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis
371 infection to active disease. 2017.
- 372 11. Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, et al. Treatment Strategy for
373 Rifampin-Susceptible Tuberculosis. *New England Journal of Medicine*. 2023 Mar
374 9;388(10):873–87.
- 375 12. Gray AT, Macpherson L, Carlin F, Sossen B, Richards AS, Kik SV, et al. Treatment for
376 radiographically active, sputum culture-negative pulmonary tuberculosis: A systematic review
377 and meta-analysis. *PLOS ONE*. 2023 Nov 16; 18(11):e0293535.
- 378 13. Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, et al.
379 Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. *The
380 Lancet Infectious Diseases*. 2021 Mar 1; 21(3):354–65.

- 381 14. Mangham LJ, Hanson K, McPake B. How to do (or not to do) ... Designing a discrete choice
382 experiment for application in a low-income country. *Health Policy and Planning*. 2009 Mar 1
383 ;24(2):151–8.
- 384 15. Weber S. A Step-by-Step Procedure to Implement Discrete Choice Experiments in Qualtrics.
385 *Social Science Computer Review*. 2019 Nov 3; 0894439319885317.
- 386 16. Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete Choice Experiments in Health
387 Economics: Past, Present and Future. *PharmacoEconomics*. 2019 Feb 1 ;37(2):201–26.
- 388 17. Quaife M, Terris-Prestholt F, Di Tanna GL, Vickerman P. How well do discrete choice
389 experiments predict health choices? A systematic review and meta-analysis of external validity.
390 *Eur J Health Econ*. 2018 Nov;19(8):1053–66.
- 391 18. Amaya-amaya M, Gerald K, Ryan M. Discrete choice experiments in a nutshell. In: *Using
392 discrete choice experiments to value health care*. Springer; 2008. p. 13–4.
- 393 19. Soko RN, Burke RM, Feasey HRA, Sibande W, Nliwasa M, Henrion MYR, et al. Effects of
394 Coronavirus Disease Pandemic on Tuberculosis Notifications, Malawi. *Emerg Infect Dis*. 2021
395 Jul;27(7):1831–9.
- 396 20. Malawi Ministry of Health. *Malawi Population-based HIV Impact Assessment 2020-2021
397 (MPHIA 2020-2021): Final Report*. Lilongwe: MOH, Malawi; 2022 Nov.
- 398 21. Ministry of Health. *Malawi National Tuberculosis Control Programme Manual 8th edition*.
399 Government of Malawi; 2017.
- 400 22. Foreign Exchange Rates - Reserve Bank of Malawi [Internet]. [cited 2020 Oct 21]. Available
401 from: <https://rbm.mw/Statistics/MajorRates>
- 402 23. Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, et al.
403 Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR
404 Conjoint Analysis Experimental Design Good Research Practices Task Force. *Value in Health*.
405 2013 Jan 1 ;16(1):3–13.
- 406 24. Lancsar E, Louviere J. Conducting Discrete Choice Experiments to Inform Healthcare Decision
407 Making. *Pharmacoeconomics*. 2008 Aug 1 ;26(8):661–77.
- 408 25. Campbell D, Boeri M, Doherty E, George Hutchinson W. Learning, fatigue and preference
409 formation in discrete choice experiments. *Journal of Economic Behavior & Organization*. 2015
410 Nov 1;119:345–63.
- 411 26. Lim RK, Semitala FC, Atuhumuza E, Sabiti L, Namakula-Katende J, Muyindike WR, et al.
412 Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in
413 a routine HIV program setting in Uganda. *PLoS One*. 2021;16(2):e0246113.
- 414 27. Guo N, Marra CA, FitzGerald JM, Elwood RK, Anis AH, Marra F. Patient Preference for Latent
415 Tuberculosis Infection Preventive Treatment: A Discrete Choice Experiment. *Value in Health*.
416 2011 Sep 1 ;14(6):937–43.
- 417 28. Aibana O, Dauria E, Kiriazova T, Makarenko O, Bachmaha M, Rybak N, et al. Patients'
418 perspectives of tuberculosis treatment challenges and barriers to treatment adherence in Ukraine:
419 a qualitative study. *BMJ Open* . 2020 Jan 1 ;10(1):e032027.

- 420 29. Cook AR, Zhao X, Chen MIC, Finkelstein EA. Public preferences for interventions to prevent
421 emerging infectious disease threats: a discrete choice experiment. *BMJ Open*. 2018 Feb 1
422 ;8(2):e017355.
- 423 30. Yuen CM, Millones AK, Galea JT, Puma D, Jimenez J, Lecca L, et al. Toward patient-centered
424 tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru.
425 *BMC Public Health*. 2021 Jan 11;21(1):121.
- 426 31. Marahatta SB, Yadav RK, Giri D, Lama S, Rijal KR, Mishra SR, et al. Barriers in the access,
427 diagnosis and treatment completion for tuberculosis patients in central and western Nepal: A
428 qualitative study among patients, community members and health care workers. *PLOS ONE*.
429 2020 Jan 15 ;15(1):e0227293.
- 430 32. Muttamba W, Tumwebaze R, Mugenyi L, Batte C, Sekibira R, Nkolo A, et al. Households
431 experiencing catastrophic costs due to tuberculosis in Uganda: magnitude and cost drivers. *BMC*
432 *Public Health*. 2020 Sep 16;20(1):1409.
- 433 33. Kamchedzera W, Maheswaran H, Squire SB. Economic costs of accessing tuberculosis (TB)
434 diagnostic services in Malawi: an analysis of patient costs from a randomised controlled trial of
435 computer-aided chest x-ray interpretation [version 1; peer review: 2 approved with reservations].
436 *Wellcome Open Research*. 2021 ;153(6).
- 437 34. Sichali JM, Khan JAK, Gama EM, Banda HT, Namakhoma I, Bongololo G, et al. Direct costs of
438 illness of patients with chronic cough in rural Malawi-Experiences from Dowa and Ntchisi
439 districts. *PloS One*. 2019;14(12):e0225712.
- 440 35. Ukwaja KN, Alobu I, Lgwenyi C, Hopewell PC. The High Cost of Free Tuberculosis Services:
441 Patient and Household Costs Associated with Tuberculosis Care in Ebonyi State, Nigeria. *PLoS*
442 *ONE*. 2013 ;8(8).
- 443 36. Fuady A, Houweling TAJ, Mansyur M, Richardus JH. Catastrophic total costs in tuberculosis-
444 affected households and their determinants since Indonesia's implementation of universal health
445 coverage. *Infectious Diseases of Poverty*. 2018 Jan 12 ;7(1):3.
- 446 37. Johnson FR, Yang JC, Reed SD. The Internal Validity of Discrete Choice Experiment Data: A
447 Testing Tool for Quantitative Assessments. *Value in Health*. 2019 Feb 1;22(2):157–60.


448 Supporting information

449 S1 Appendix. Discrete choice experiment questionnaire (English)

450 S2 Appendix. Discrete choice experiment questionnaire (Chichewa)

451 S3 Appendix. Discrete choice experiment visual aid.

● Disease risk: 10%
 ● Disease risk: 30%
 ● Disease risk: 50%
 ● Reference



medRxiv preprint doi: <https://doi.org/10.1101/2023.12.20.23300332>; this version posted December 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1